Trio Pharmaceuticals Raises $2.2 Million Seed PHARMA: Bootstrapped Firm Gains Steam for Dual Approach to Cancer Treatment.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Author(s): CLEMETSON, JEFF
  • Source:
    San Diego Business Journal. 4/10/2023, Vol. 44 Issue 15, p6-6. 1/2p.
  • Additional Information
    • Abstract:
      The article states that with SeedFolio, NuFund Venture Group and Friedman BioVentures leading the way, Trio Pharmaceuticals, San Diego, California, U.S., has raised a substantial amount of seed funding to push forward with its three-pronged method of cancer treatment. It highlights that TRIObody Drug Conjugate (TDC), which is a unique type of antibody-drug conjugate (ADC), uses directed payload delivery to halt the growth of tumors and immunosuppression.